Merit Medical Systems Inc. (MMSI) Tops Q4 EPS by 6c, Revenues Beat; Offers FY20 EPS Guidance Above Consensus

Merit Medical Systems Inc. (NASDAQ: MMSI) reported Q4 EPS of $0.40, $0.06 better than the analyst estimate of $0.34. Revenue for the quarter came in at $257.9 million versus the consensus estimate of $252.31 million.

• Q4 2019 worldwide revenue of $257.9 million, up 10.6% as reported over Q4 2018
• Q4 2019 core revenue on a comparable, constant currency basis* up 8.5% over Q4 2018
• Q4 2019 GAAP loss per share was $(0.08), compared to GAAP EPS of $0.16 in Q4 2018
• Q4 2019 non-GAAP EPS* was $0.40, compared to $0.48 in Q4 2018

“We are pleased with the strong performance across our business during the fourth quarter and that the integration of our most recent acquisitions is largely complete,” said Fred P. Lampropoulos, Merit’s Chairman and Chief Executive Officer. “As noted in our recent press release, we have received a number of important new regulatory approvals. These approvals, along with other internally developed products scheduled for release and a full pipeline of new products in the works, give us confidence in the future growth of the company.”

GUIDANCE:

Merit Medical Systems Inc. sees FY2020 EPS of $1.58-$1.68, versus the consensus of $1.56.

For earnings history and earnings-related data on Merit Medical Systems Inc. (MMSI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c